A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
The current desirable endpoint of treatment against chronic hepatitis B virus infection (cHBV) is to achieve a functional cure, which is defined as HBsAg loss (sAg-L) with or without anti-HBs seroconversion. However, the immunological features that are associated with functional cure have not been studied in detail. Here, a total of 172 cHBV patients including 31 sAg-L patients, and 24 healthy individuals were examined for their T cell phenotypic profile and HBV-specific T cell responses bydoi:10.1101/2020.11.16.382838 fatcat:swvs3otrgjbhdetk43qalph53u